KR20170015521A - 포스파티딜이노시톨 3-키나제 억제제 - Google Patents
포스파티딜이노시톨 3-키나제 억제제 Download PDFInfo
- Publication number
- KR20170015521A KR20170015521A KR1020177001682A KR20177001682A KR20170015521A KR 20170015521 A KR20170015521 A KR 20170015521A KR 1020177001682 A KR1020177001682 A KR 1020177001682A KR 20177001682 A KR20177001682 A KR 20177001682A KR 20170015521 A KR20170015521 A KR 20170015521A
- Authority
- KR
- South Korea
- Prior art keywords
- alkylene
- oxo
- amino
- diamino
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YQDOMQGRYFOVLB-VIFPVBQESA-N C[C@@H](C(N(c1cc(F)cc(F)c1)C(c1c(CCC(N)=O)cc2)=O)=Nc1c2F)Nc1nc(N)nc(N)c1Cl Chemical compound C[C@@H](C(N(c1cc(F)cc(F)c1)C(c1c(CCC(N)=O)cc2)=O)=Nc1c2F)Nc1nc(N)nc(N)c1Cl YQDOMQGRYFOVLB-VIFPVBQESA-N 0.000 description 1
- LKNVBFDROWOHEN-VIFPVBQESA-N C[C@@H](C(N1c2cc(F)cc(F)c2)=Nc2cccc(Cl)c2C1=O)Nc(nc(C)nc1N)c1Br Chemical compound C[C@@H](C(N1c2cc(F)cc(F)c2)=Nc2cccc(Cl)c2C1=O)Nc(nc(C)nc1N)c1Br LKNVBFDROWOHEN-VIFPVBQESA-N 0.000 description 1
- OJXCRLCQACFFMY-VIFPVBQESA-N C[C@@H](C(N1c2cc(F)cc(F)c2)=Nc2cccc(Cl)c2C1=O)Nc(nc(N)nc1Cl)c1C#N Chemical compound C[C@@H](C(N1c2cc(F)cc(F)c2)=Nc2cccc(Cl)c2C1=O)Nc(nc(N)nc1Cl)c1C#N OJXCRLCQACFFMY-VIFPVBQESA-N 0.000 description 1
- GCNHQQDMCNVFLR-AWEZNQCLSA-N C[C@@H](C(N1c2cccc(F)c2)=Nc2cccc(S(CCO)(=O)=O)c2C1=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(N1c2cccc(F)c2)=Nc2cccc(S(CCO)(=O)=O)c2C1=O)NC(OC(C)(C)C)=O GCNHQQDMCNVFLR-AWEZNQCLSA-N 0.000 description 1
- NIAIBHPRNOAUSN-SOGBHIHOSA-N C[C@@H](C(N1c2ccccc2)=Nc2cccc(/C=C/C=O)c2C1=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(N1c2ccccc2)=Nc2cccc(/C=C/C=O)c2C1=O)NC(OC(C)(C)C)=O NIAIBHPRNOAUSN-SOGBHIHOSA-N 0.000 description 1
- PLKGAVRXSKKTHS-HNNXBMFYSA-N C[C@@H](C(N1c2ccccc2)=Nc2cccc(CCC(N)=O)c2C1=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(N1c2ccccc2)=Nc2cccc(CCC(N)=O)c2C1=O)NC(OC(C)(C)C)=O PLKGAVRXSKKTHS-HNNXBMFYSA-N 0.000 description 1
- OFGZBSYIKRDFFE-SFHVURJKSA-N C[C@@H](C(N1c2ccccc2)=Nc2cccc(CCCN3CCOCC3)c2C1=O)Nc(nc(N)nc1N)c1C#N Chemical compound C[C@@H](C(N1c2ccccc2)=Nc2cccc(CCCN3CCOCC3)c2C1=O)Nc(nc(N)nc1N)c1C#N OFGZBSYIKRDFFE-SFHVURJKSA-N 0.000 description 1
- CIYIAGNLSXJOJR-NSHDSACASA-N C[C@@H](C(N1c2ccccc2)=Nc2cccc(Cl)c2C1=O)Nc(nc(nc1N)Cl)c1C#N Chemical compound C[C@@H](C(N1c2ccccc2)=Nc2cccc(Cl)c2C1=O)Nc(nc(nc1N)Cl)c1C#N CIYIAGNLSXJOJR-NSHDSACASA-N 0.000 description 1
- MBZGDNNBVHJZBJ-KRWDZBQOSA-N C[C@@H](C(N1c2ccccc2)=Nc2cccc(OCCN3CCCC3)c2C1=O)Nc1nc(N)nc(N)c1C#N Chemical compound C[C@@H](C(N1c2ccccc2)=Nc2cccc(OCCN3CCCC3)c2C1=O)Nc1nc(N)nc(N)c1C#N MBZGDNNBVHJZBJ-KRWDZBQOSA-N 0.000 description 1
- GNZXPAYCWAHIQH-ACJLOTCBSA-N NCC(N[C@H](C[C@H]1C(N2c3ccccc3)=Nc(cccc3Cl)c3C2=O)CN1c(nc(N)nc1N)c1C#N)=O Chemical compound NCC(N[C@H](C[C@H]1C(N2c3ccccc3)=Nc(cccc3Cl)c3C2=O)CN1c(nc(N)nc1N)c1C#N)=O GNZXPAYCWAHIQH-ACJLOTCBSA-N 0.000 description 1
- HNVQQPZDIGHQII-KRWDZBQOSA-N Nc1nc(N)nc(N(CCC2)[C@@H]2C(N2c3cc(F)cc(F)c3)=Nc3cccc(Cl)c3C2=O)c1C#N Chemical compound Nc1nc(N)nc(N(CCC2)[C@@H]2C(N2c3cc(F)cc(F)c3)=Nc3cccc(Cl)c3C2=O)c1C#N HNVQQPZDIGHQII-KRWDZBQOSA-N 0.000 description 1
- VBFRFRVPVIHNJU-HNNXBMFYSA-N Nc1nc(N)nc(N(CCOC2)[C@@H]2C(N2c3ccccc3)=Nc(cccc3Cl)c3C2=O)c1Cl Chemical compound Nc1nc(N)nc(N(CCOC2)[C@@H]2C(N2c3ccccc3)=Nc(cccc3Cl)c3C2=O)c1Cl VBFRFRVPVIHNJU-HNNXBMFYSA-N 0.000 description 1
- OTYATIHHKUGQAX-SJCJKPOMSA-N Nc1nc(N)nc(N(C[C@H](C2)NC(C(F)(F)F)=O)[C@@H]2C(N2c3ccccc3)=Nc3cccc(Cl)c3C2=O)c1C#N Chemical compound Nc1nc(N)nc(N(C[C@H](C2)NC(C(F)(F)F)=O)[C@@H]2C(N2c3ccccc3)=Nc3cccc(Cl)c3C2=O)c1C#N OTYATIHHKUGQAX-SJCJKPOMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016194P | 2014-06-24 | 2014-06-24 | |
| US62/016,194 | 2014-06-24 | ||
| PCT/US2015/037234 WO2015200352A1 (en) | 2014-06-24 | 2015-06-23 | Phosphatidylinositol 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170015521A true KR20170015521A (ko) | 2017-02-08 |
Family
ID=53674285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177001682A Abandoned KR20170015521A (ko) | 2014-06-24 | 2015-06-23 | 포스파티딜이노시톨 3-키나제 억제제 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9765060B2 (enExample) |
| EP (1) | EP3160960B1 (enExample) |
| JP (2) | JP6391718B2 (enExample) |
| KR (1) | KR20170015521A (enExample) |
| CN (1) | CN106459008A (enExample) |
| AR (1) | AR100975A1 (enExample) |
| AU (1) | AU2015280138B2 (enExample) |
| BR (1) | BR112016029846A2 (enExample) |
| CA (1) | CA2953820A1 (enExample) |
| EA (1) | EA201692487A1 (enExample) |
| ES (1) | ES2900812T3 (enExample) |
| HK (1) | HK1231474A1 (enExample) |
| IL (1) | IL249404A0 (enExample) |
| MA (1) | MA40045A (enExample) |
| MX (1) | MX2016017110A (enExample) |
| NZ (1) | NZ727185A (enExample) |
| SG (1) | SG11201610341PA (enExample) |
| TW (1) | TW201625558A (enExample) |
| WO (1) | WO2015200352A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012121953A1 (en) | 2011-03-08 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treating lymphoid malignancy |
| ES2763103T3 (es) | 2014-06-13 | 2020-05-27 | Gilead Sciences Inc | Inhibidor de la fosfatidilinositol 3-quinasa |
| JP6454736B2 (ja) | 2014-06-13 | 2019-01-16 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| BR112016028876A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. |
| CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| US9944639B2 (en) | 2014-07-04 | 2018-04-17 | Lupin Limited | Quinolizinone derivatives as PI3K inhibitors |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TW201815787A (zh) * | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
| US10396145B2 (en) * | 2017-01-12 | 2019-08-27 | Micron Technology, Inc. | Memory cells comprising ferroelectric material and including current leakage paths having different total resistances |
| WO2018237007A1 (en) * | 2017-06-22 | 2018-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer |
| CN111386264A (zh) * | 2017-07-31 | 2020-07-07 | 纽约市哥伦比亚大学理事会 | 用于治疗t-细胞急性淋巴细胞白血病的化合物、组合物和方法 |
| WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| AU2019345706B2 (en) * | 2018-09-27 | 2024-02-22 | Shanghai Yingli Pharmaceutical Co., Ltd | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
| US20220348558A1 (en) * | 2019-09-05 | 2022-11-03 | Wisconsin Alumni Research Foundation | Inhibitors of encephalitic alphaviruses |
| CN110590681B (zh) * | 2019-09-30 | 2021-06-01 | 中山大学 | 一种新型喹唑啉酮类化合物及其制备方法和应用 |
| UY38934A (es) * | 2019-10-29 | 2021-05-31 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| CN118373824A (zh) * | 2020-04-09 | 2024-07-23 | 成都赜灵生物医药科技有限公司 | 取代喹唑啉-4-酮类化合物及其制备方法和用途 |
| WO2024064024A1 (en) * | 2022-09-19 | 2024-03-28 | Onkure, Inc. | ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785363B1 (ko) | 2000-04-25 | 2007-12-18 | 이코스 코포레이션 | 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제 |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX358640B (es) * | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CA2846431A1 (en) * | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US9029384B2 (en) * | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
| WO2014128612A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| ES2763103T3 (es) * | 2014-06-13 | 2020-05-27 | Gilead Sciences Inc | Inhibidor de la fosfatidilinositol 3-quinasa |
| CN106459005A (zh) * | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
-
2015
- 2015-06-23 MX MX2016017110A patent/MX2016017110A/es unknown
- 2015-06-23 WO PCT/US2015/037234 patent/WO2015200352A1/en not_active Ceased
- 2015-06-23 EA EA201692487A patent/EA201692487A1/ru unknown
- 2015-06-23 AR ARP150102013A patent/AR100975A1/es unknown
- 2015-06-23 BR BR112016029846A patent/BR112016029846A2/pt not_active IP Right Cessation
- 2015-06-23 NZ NZ727185A patent/NZ727185A/en not_active IP Right Cessation
- 2015-06-23 CN CN201580034671.2A patent/CN106459008A/zh active Pending
- 2015-06-23 MA MA040045A patent/MA40045A/fr unknown
- 2015-06-23 ES ES15739079T patent/ES2900812T3/es active Active
- 2015-06-23 AU AU2015280138A patent/AU2015280138B2/en not_active Ceased
- 2015-06-23 JP JP2016574424A patent/JP6391718B2/ja not_active Expired - Fee Related
- 2015-06-23 SG SG11201610341PA patent/SG11201610341PA/en unknown
- 2015-06-23 CA CA2953820A patent/CA2953820A1/en not_active Abandoned
- 2015-06-23 US US14/747,931 patent/US9765060B2/en active Active
- 2015-06-23 KR KR1020177001682A patent/KR20170015521A/ko not_active Abandoned
- 2015-06-23 EP EP15739079.0A patent/EP3160960B1/en active Active
- 2015-06-23 HK HK17105165.9A patent/HK1231474A1/zh unknown
- 2015-06-24 TW TW104120373A patent/TW201625558A/zh unknown
-
2016
- 2016-12-06 IL IL249404A patent/IL249404A0/en unknown
-
2017
- 2017-08-17 US US15/680,045 patent/US20180065953A1/en not_active Abandoned
-
2018
- 2018-03-19 JP JP2018051249A patent/JP2018090644A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106459008A (zh) | 2017-02-22 |
| EA201692487A1 (ru) | 2017-06-30 |
| AR100975A1 (es) | 2016-11-16 |
| CA2953820A1 (en) | 2015-12-30 |
| MX2016017110A (es) | 2017-05-01 |
| BR112016029846A2 (pt) | 2017-08-22 |
| AU2015280138B2 (en) | 2018-06-14 |
| WO2015200352A1 (en) | 2015-12-30 |
| HK1231474A1 (zh) | 2017-12-22 |
| JP6391718B2 (ja) | 2018-09-19 |
| IL249404A0 (en) | 2017-02-28 |
| SG11201610341PA (en) | 2017-01-27 |
| US20160024054A1 (en) | 2016-01-28 |
| US9765060B2 (en) | 2017-09-19 |
| TW201625558A (zh) | 2016-07-16 |
| ES2900812T3 (es) | 2022-03-18 |
| AU2015280138A1 (en) | 2016-12-22 |
| NZ727185A (en) | 2018-04-27 |
| JP2017519021A (ja) | 2017-07-13 |
| MA40045A (fr) | 2021-06-02 |
| EP3160960B1 (en) | 2021-10-13 |
| US20180065953A1 (en) | 2018-03-08 |
| EP3160960A1 (en) | 2017-05-03 |
| JP2018090644A (ja) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170015521A (ko) | 포스파티딜이노시톨 3-키나제 억제제 | |
| JP6454736B2 (ja) | ホスファチジルイノシトール３−キナーゼ阻害剤 | |
| JP6455995B2 (ja) | ホスファチジルイノシトール３−キナーゼ阻害剤 | |
| KR20170015508A (ko) | 포스파티딜이노시톨 3-키나제 억제제로서의 퀴나졸리논 유도체 | |
| JP6346964B2 (ja) | ホスファチジルイノシトール３−キナーゼ阻害剤 | |
| KR20170010063A (ko) | 포스파티딜이노시톨 3-키나제 억제제 | |
| AU2020300586A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| HK1231078A1 (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
| HK1233646A1 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HK1233642A1 (en) | Phosphatidylinositol 3-kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0105 | International application |
Patent event date: 20170119 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170119 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180319 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20180620 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20180319 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20180620 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20180518 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20170119 Comment text: Amendment to Specification, etc. |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20180807 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20180718 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20180620 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20180518 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170119 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
| X701 | Decision to grant (after re-examination) | ||
| PC1904 | Unpaid initial registration fee |